BPK Bespak

RNS Number:8481D
Bespak PLC
14 September 2007


                     Bespak - Interim Management Statement

Bespak plc, a leader in medical devices for inhaled drug delivery and
anaesthesia, issues today its Interim Management Statement for the period, 29
April 2007 to 14 September 2007.

Trading for period has been in line with the Board's expectations with good
performances in both our inhaled drug delivery and anaesthesia segments.

On 27 June 2007 we announced that Nektar Therapeutics and Pfizer had revised 
their short term forecasts for their Exubera(R) inhalation device and as a 
result we were embarking on a consultation process with our employees involved 
in its production. We remain in detailed discussions with Nektar on potential 
strategies to address the short- to medium-term supply of the Exubera(R) 
inhaler.

On 17 July 2007, we acquired, for a modest consideration, through a newly formed
subsidiary company (Integrated Aluminium Components Limited), certain assets of
Decorpart Ltd from its administrators. Decorpart produces ferrules used in our
metered dose inhaler valves and this acquisition secures the supply chain for
our business, and supplies third parties.

The Company will hold its AGM on September 26th 2007 and publish interim results
in December 2007.

For further information, please contact:
Bespak plc
Mark Throdahl, Chief Executive             Tel: +44 (0) 1908 552600
Jonathan Glenn, Group Finance Director

Maitland
Liz Morley                                 Tel: +44 (0) 207 3795151
Brian Hudspith

This Interim Management Statement is prepared for and addressed only to the
Company's shareholders as a whole and to no other person. The Company, its
directors, employees, agents or advisers do not accept or assume responsibility
to any other person to whom this Interim Management Statement is shown or into
whose hands it may come and any such responsibility or liability is expressly
disclaimed.  Statements contained in this Interim Management Statement are based
on the knowledge and information available to the Company's Directors at the
date it was prepared and therefore the facts stated and views expressed may
change after that date. By their nature, the statements concerning the risks and
uncertainties facing the Company in this Interim Management Statement involve
uncertainty since future events and circumstances can cause results and
developments to differ materially from those anticipated.  To the extent that
this Interim Management Statement contains any statement dealing with any time
after the date of its preparation such statement is merely predictive and
speculative as it relates to events and circumstances which are yet to occur.
The Company undertakes no obligation to update these forward-looking statements.

About Bespak plc

Bespak plc is a leader in medical devices for inhaled drug delivery and
anaesthesia. The Group develops drug delivery systems for the pharmaceutical
industry and disposable airway management products for critical care settings in
hospitals.

Bespak develops and manufactures metered dose inhaler valves, actuators,
compliance aids, dry powder devices, disposable face masks, breathing circuits
and laryngeal tubes. The Group has facilities in King's Lynn and Milton Keynes
in the UK, Indianapolis, Indiana and Kent, Ohio in the US, and a liaison office
in Mumbai, India. Bespak is a public company quoted on the full list of the
London Stock Exchange (LSE: BPK). For more information, please visit
www.bespak.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
IMSGUURUBUPMGRW

Bespak (LSE:BPK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Bespak (LSE:BPK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024